Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.35 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916109 | 0.94 | POLB (0.52) | POLBSIGMAR1ACACBACACAHSD17B10 | |
| SCHEMBL8227343 | 0.82 | POLB (0.70) | POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL4474136 | 0.81 | SIGMAR1 (0.43) | SIGMAR1L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL12606996 | 0.81 | SIGMAR1 (0.43) | SIGMAR1ACACBACACAL3MBTL3L3MBTL1 | |
| SCHEMBL19203827 | 0.81 | POLB (0.52) | POLBACACBACACAHSD17B10L3MBTL3 | |
| SCHEMBL26138783 | 0.80 | SIGMAR1 (0.42) | SIGMAR1ACACBACACAL3MBTL3L3MBTL1 | |
| SCHEMBL19196470 | 0.80 | SIGMAR1 (0.42) | SIGMAR1ACACBACACAL3MBTL3L3MBTL1 | |
| SCHEMBL19196412 | 0.79 | LMNA (0.46) | SIGMAR1ACACBACACALMNA | |
| SCHEMBL12156648 | 0.78 | POLB (0.57) | POLBACACBACACAHSD17B10L3MBTL3 | |
| SCHEMBL11916124 | 0.77 | SIGMAR1 (0.54) | POLBSIGMAR1HSD17B10LMNAL3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | POLB 2336/4885SIGMAR1 3576/4885ACACB 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.